COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

February 23, 2023
Paving the way for PDAC Precision Medicine

Despite extensive clinical and scientific efforts, pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in Korea and around the world. Prior analyses of PDAC tissues have identified key genomic features of the disease, but proteomic signatures have not...
February 8, 2023
CPTAC Assays Used to Analyze Aggressive Brain Tumors

Diffuse intrinsic pontine gliomas (DIPG) are a type of brain tumor that is extremely aggressive and have a historically poor prognosis. To improve these outcomes, the development of novel therapies and methods to measure their efficacy are critical.
January 11, 2023
APOLLO Researchers Uncover Novel Proteogenomic Features of Lung Cancer

The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network is a cancer...
January 3, 2023
CPTAC Researchers Molecularly Stratify Aggressive Histopathologic Subtypes of Kidney Cancer

Renal cell carcinoma (RCC) is among the ten most diagnosed cancers worldwide for men and women and comprises a wide array of histologically and genetically defined subtypes involving the kidney. Clear cell RCC (ccRCC) accounts for ~75% of all RCC cases and the majority of renal cancer-associated...
November 1, 2022
CPTAC Data Used to Develop Cutting Edge Tools for Illuminating the Druggable Genome

Recently, Dr. Bing Zhang and his team from the Lester and Sue Smith Breast Center at Baylor College of Medicine were awarded a two-year funding opportunity to develop Cutting Edge Informatics Tools for the NIH Common Fund program Illuminating the Druggable Genome (IDG).
October 20, 2022
CPTAC Researchers Document Differential Expression of Glycosylation Sites in Liver and Pancreatic Cancer

Core fucosylation (CF) of N-linked glycoproteins is linked with the functions of glycoproteins in many physiological and pathological processes. This feature has a high potential for use in the detection of cancer as well as the development of targeted therapies. For example, high levels of alpha-...
September 26, 2022
FDA and NIH Sign Memorandum of Understanding: Interagency Collaboration to Advance Proteogenomics Research

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of a memorandum of understanding (MOU) bolstering its ongoing collaboration with the U.S. Food and Drug Administration (FDA). This MOU provides a framework that will enable and encourage the...
September 14, 2022
Ex Vivo Drug Sensitivity Testing in AML: Improving Response Predictability Using Proteomic Measurements

Genetic heterogeneity amongst leukemic cells is a major contributor to low survival rates and poor clinical outcomes for patients with acute myeloid leukemia (AML). This diversity drives complex signaling pathways at the protein level which necessitate individualized treatment protocols for each...
August 24, 2022
CPTAC Investigators Analyze Proteogenomic Markers of Chemotherapy Resistance and Response in Triple Negative Breast Cancer

CPTAC investigators from Baylor College of Medicine and the Broad Institute of MIT and Harvard in collaboration with oncologists at Washington University in St. Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy...
August 18, 2022
Collaborating with Major International Partners - NCI Welcomes Renewed Commitments to the Cancer Moonshot with Australia, Canada, and Germany

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of partnerships with Australia, Canada, and Germany. These partnerships, through memoranda of understanding (MOUs) to the NCI Cancer Moonshot International...

Pages

more

View all News and Announcements

NIH…Turning Discovery Into Health®